An antibody-drug conjugate (AZD0901) for advanced stomach, pancreatic, and bile duct cancers

You may qualify if

• The list below is a summarised eligibility criteria for the study - refer to the study protocol for full criteria.

You may qualify if

• Participant must be ≥ 18 years or the legal age of consent at the time of signing the ICF.
• Participants who are CLDN18.2 positive.
• Must have at least one measurable lesion according to RECIST v1.1.
• ECOG performance status of 0 to 1 with no deterioration over the previous 2 weeks prior first day of dosing.
• Predicted life expectancy of ≥ 12 weeks.
• Adequate organ and bone marrow function as defined by protocol.
• Body weight > 35 kg.
• Participants are willing to comply with contraception requirements. Sub study 1 Specific Inclusion criteria:; Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction.; Advanced or metastatic GC/GEJC.; Maximum 2 prior lines of systemic treatment for unresectable or metastatic disease. Sub study 2 Specific Inclusion criteria:; Participants diagnosed with histologically confirmed metastatic or advanced PDAC.; Availability of an archival sample or a fresh tumour biopsy taken at screening.; No prior treatments for unresectable or metastatic disease. Prior neoadjuvant/adjuvant chemotherapy is permitted as long as participants progressed ≥ 6 months (183 days) from the last dose. Sub study 3 Specific
• Histologically confirmed, unresectable advanced, or metastatic adenocarcinoma of biliary tract, including cholangiocarcinoma (intrahepatic or extrahepatic) and gallbladder carcinoma (NOTE: Ampullary cancers are not eligible).
• Documented radiographic or clinical disease progression on or after at least one prior regimen and maximum 2 prior lines of systemic treatment for unresectable or metastatic disease.

You can't join if

• Unstable or active peptic ulcer disease or digestive tract bleeding including but not limited to clinically significant bleeding in the setting of prior CLDN18.2 directed therapy.
• Participants with clinically significant ascites that require drainage.
• A history of drug-induced non-infectious ILD/pneumonitis.
• Central nervous system metastases or CNS pathology.
• Peripheral neuropathy, sensory, or motor ≥ Grade 2 at screening.
• History of another primary malignancy.
• Prior exposure to any MMAE-based ADC.
• Prior exposure to any CLDN18.2 targeted agents except anti-CLDN18.2 monoclonal antibody. Sub study 1 Specific Exclusion criteria:; Participants with HER2-positive (3+ by IHC, or 2+ by IHC, and positive by ISH) or indeterminate GC/GEJC unless they have failed/not tolerated/or are not eligible for standard anti-HER2 therapy, where available.; Any factors that increase the risk of QTc prolongation or risk of arrhythmic events.; The use of concomitant medications known to prolong the QT/QTc interval. Sub study 2 Specific Exclusion criteria:; Known DPD enzyme deficiency based on local testing where testing is SoC.; Use of strong inhibitor or inducer of UGT1A1.; Use of strong inhibitors or inducers of CYP3A4.; Known homozygous for the UGT1A1*28 allele based on local testing where testing is SoC. Sub study 3 Specific
• Clinically significant biliary obstruction that has not resolved before enrollment.